Annexon, Inc. (ANNX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Annexon: Lead GBS Therapy Stokes Near-Term Potential
Annexon is a speculative Buy due to its late-stage Tanruprubart program targeting the high unmet need in Guillain-Barré Syndrome. Tanruprubart could become the standard of care for GBS if approved, given the lack of FDA-approved therapies and limited competition. The company faces near-term risks: delayed regulatory filings, high cash burn, and a likely need for additional funding within a year.
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck
Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting with the FDA in H1 2025. The company has $312 million in cash, enough to fund operations into H2 2026, reducing the need for imminent fundraising. Annexon is also developing ANX007 for Geographic Atrophy, with key milestones including enrollment completion in H2 2025 and topline data in H2 2026.
Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)
On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totaling $19,104.
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Annexon's ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address autoimmune, neurodegenerative, and ophthalmic conditions. The company's pipeline includes ANX005, ANX007, and ANX1502. Due to its advanced development stage, ANX005 is the primary value driver.
Are Medical Stocks Lagging Annexon (ANNX) This Year?
Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet
The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS IGOS phase 3 study, using ANX005 for the treatment of patients with GBS, expected 1st half of 2025. If the primary endpoint of the RWS IGOS protocol study achieves a positive outcome, then a BLA filing is expected in the 1st half 2025.
Annexon's neurological disorder drug meets main goal of late-stage study
Annexon Inc said on Tuesday its experimental drug to treat a rare neurological disorder met the main goal of a late-stage trial.
